|
Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Further Reading from MarketBeat Media
Viking Therapeutics Faces Timeline Risk—But Upside Could Be HugeAuthor: Chris Markoch. Date Posted: 5/1/2026. 
Key Points
- Viking Therapeutics stock reflects the long timelines of clinical-stage biotech, with key VK2735 trial results not expected until 2027.
- The company’s dual-track GLP-1 strategy, including injectable and oral drugs, positions it to compete in a fast-growing weight-loss market.
- Strong cash reserves support operations into 2028, but dilution risk and rising competition remain key concerns for investors.
- Special Report: Have $500? Invest in Elon’s AI Masterplan
Buy the story, sell the news. That’s a reasonable explanation for why Viking Therapeutics (NASDAQ: VKTX) fell more than 3% the day the company delivered its Q1 2026 earnings report. Investors should remember Viking is a pre-revenue, clinical-stage biotechnology company, so headline earnings numbers aren’t the right yardstick. Instead, the key is where the company stands in the FDA timeline: progress through trials (and the time and cost that requires) determines risk and potential reward. Defining the Opportunity
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
Viking is a relatively new player in the GLP-1 space, which is currently dominated by Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO). Those leaders face the challenge of scaling production to meet demand—a good problem to have, but one that leaves openings for smaller competitors. Rather than being just another entrant, Viking is pursuing a two-track approach: both an injectable (subcutaneous) and an oral formulation of its candidate are advancing through clinical development. That strategy could differentiate Viking if both formulations reach the market. Progress Takes TimeThe injectable candidate, VK2735, is further along. Its Phase 2 (VENTURE) trial completed in 2025 and was published in the peer-reviewed journal Obesity in January 2026. Viking has reported full enrollment in the VANQUISH-1 (adults with obesity) and VANQUISH-2 (adults with obesity and type 2 diabetes) trials. These are 78-week studies, so investors should not expect topline results until the second half of 2027 at the earliest. The oral formulation of VK2735 is also progressing. Viking completed an end-of-Phase 2 meeting with the FDA in December 2025 and, based on agency feedback, plans to advance the oral candidate into Phase 3 in Q4 2026—roughly six months behind the injectable timeline. That lag matters because Viking doesn’t have the field to itself. Competitors like Lilly already offer oral GLP-1 options, which could limit Viking’s addressable market even if it secures approval. Progress Takes MoneyAdvancing two formulations through late-stage trials will be capital intensive. Viking ended the quarter with about $603 million and believes that amount is sufficient to fund operations into 2028, which should cover the injectable program through its current clinical phases. To help mitigate execution risk, Viking has signed a comprehensive agreement with CordenPharma. However, the company burned more cash than expected in the quarter, which likely contributed to the selloff. If Viking falls short of cash before key milestones, it may need to raise capital—likely via a dilutive share offering. The Wildcard That Could Redefine the OpportunityBeyond VK2735, Viking filed an investigational new drug (IND) application for its VK3019 candidate, a novel amylin agonist that targets both the amylin and calcitonin receptors involved in appetite and metabolic control. Viking believes dual activation of those receptors could be an attractive option for patients who aren’t candidates for GLP-1 therapies. The company plans to initiate a Phase 1 trial for VK3019 in Q2 2026. How to Make Time Your Friend With VKTXShort interest in VKTX is around 21% and institutional ownership sits near 76%, creating headwinds for retail investors. That’s reflected in the stock being down more than 14% in 2026 despite the company’s clinical progress. Still, Viking is covered by 13 analysts who assign a consensus price target of $95.50—implying potential upside of over 200% from current levels. Given the short-term volatility and the multiyear timeline for clinical readouts, a staged approach to investing may make sense. Dollar-cost averaging or building a position in tranches tied to the successful completion of key milestones can help manage downside risk while preserving exposure to potential upside. |
0 Response to "We're excited to have you on board"
Post a Comment